ZLAB
Zai Lab Limited · Healthcare
Insiders bought $66K of Zai Lab Limited in the last 12 months
1 insider bought on 2 days.
ZLAB over the last year
Largest buyers, last 12 months
ZLAB after insider buys
3 months after each buy, from the first price a copier could get.
7 buys since 2022 with 3 months of prices.
Every filing
92 insider filings since 2021, newest first
William Lis · Director
Richard Gaynor · Director
Ying Du · Chair and CEO
Frazor Titus Edmondson III · Chief Legal Officer
Ying Du · Chair and CEO
Yajing Chen · Chief Financial Officer
William Lis · Director
Ying Du · Chair and CEO
Frazor Titus Edmondson III · General Counsel
Ying Du · Chair and CEO
Joshua L Smiley · Insider
Frazor Titus Edmondson III · General Counsel
Ying Du · Chair and CEO
Rafael Amado · Insider
Joshua L Smiley · Insider
Frazor Titus Edmondson III · General Counsel
Ying Du · Chair and CEO
Yajing Chen · CFO
Rafael Amado · Insider
Richard Gaynor · Director
Joshua L Smiley · Insider
Yajing Chen · CFO
Rafael Amado · Insider
Ying Du · Chair and CEO
Frazor Titus Edmondson III · General Counsel
Ying Du · Chair and CEO
Rafael Amado · Insider
Rafael Amado · Insider
Frazor Titus Edmondson III · General Counsel
Frazor Titus Edmondson III · General Counsel
Joshua L Smiley · Insider
Richard Gaynor · Director
Frazor Titus Edmondson III · General Counsel
Joshua L Smiley · Insider
Rafael Amado · Insider
William Lis · Director
Ying Du · Chair and CEO
Frazor Titus Edmondson III · General Counsel
Ying Du · Chair and CEO
Yajing Chen · CFO
Harald Reinhart · Insider
Frazor Titus Edmondson III · General Counsel
Joshua L Smiley · Insider
Joshua L Smiley · Insider
Rafael Amado · Insider
Harald Reinhart · Insider
Ying Du · Chair and CEO
Harald Reinhart · Insider
Rafael Amado · Insider
Frazor Titus Edmondson III · General Counsel
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.